CHRNA7 and fatty liver disease: Activation of cholinergic signaling by VNS, α7nAChR agonists, and centrally acting drugs such as galantamine results in anti-inflammatory effects, alleviation of insulin resistance and hepatic steatosis, and other beneficial effects in murine models of obesity, MetS, NASH, and type 2 diabetes.